Revenio Group Oyj

Report Publication Announcement • Nov 21, 2023

Revenio Group Corporation's financial reporting and AGM in 2024

Revenio Group Corporation, Stock Exchange Release, November 21, 2023 at 4.00 p.m. (EET)

Revenio Group Corporation will publish the following financial reports in 2024:

• Financial Statements Bulletin for the year 2023 on Thursday, February 15, 2024
• Annual reporting package 2023 will be published during week 11 in 2024
• Interim report 1-3/2024 on Thursday, April 25, 2024
• Half-year financial report 1-6/2024 on Thursday, August 8, 2024
• Interim report 1-9/2024 on Thursday, October 31, 2024

The financial statements bulletin, half-year report and interim reports will be published at approximately 9.00 am Finnish time on the above dates.

The Annual General Meeting is planned to be held on Thursday, April 4, 2024. The Board of Directors of the company will convene the meeting.

A shareholder, who wishes to include an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 16, 2024. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

For further information, please contact

Robin Pulkkinen, CFO, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Key media www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation's financial reporting and AGM in 2024